Sign Out
Breast Cancer: After failure of initial chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy, Nanoxel at a dose of 220 mg/m2 administered IV over 1 hour every 3 weeks.
For the therapy of patients with breast cancer, courses of Nanoxel should not be repeated until the neutrophil count is ≥1500 cells/mm3 and the platelet count is ≥ 100,000 cells/mm3. Patients who experience severe neutropenia (neutrophil <500 cells/mm3 for a week or longer) or severe peripheral neuropathy during Nanoxel therapy should have dosage reduced by 25% for subsequent courses of Nanoxel. The incidence of neurotoxicity and the severity of neutropenia increase with dose.
Hepatic Impairment: The appropriate dose of Nanoxel for patients with bilirubin >1.5 mg/dL is not known.
No premedication to prevent hypersensitivity reactions is required prior to administration of Nanoxel.
Continue with Google